Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Otofarma SpAMIL:OTO +3.45%18 Cash-to-Debt is 0.88 as of Dec. 2024, which is 33% above its 10-year median of 0.66. GuruFocus rates MIL:OTO with a GF Score™ of 18/100. The stock has 1 warning sign investors should review. Among 842 Medical Devices & Instruments companies, Otofarma SpA ranks worse than 60.81% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Otofarma SpA's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.88.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Otofarma SpAcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.
The historical rank and industry rank for Otofarma SpA's Cash-to-Debt or its related term are showing as below:
MIL:OTO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.44 Med: 0.66 Max: 0.88
Current: 0.88
During the past 2 years, Otofarma SpA's highest Cash to Debt Ratio was 0.88. The lowest was 0.44. And the median was 0.66.
MIL:OTO's Cash-to-Debt is ranked worse than 60.81% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs MIL:OTO: 0.88
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Otofarma SpA Cash-to-Debt Related Terms
Otofarma SpA Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Otofarma SpA's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Otofarma SpA Cash-to-Debt Chart
Otofarma SpA Annual Data
Trend
Dec23
Dec24
Cash-to-Debt
0.49
1.35
Otofarma SpA Semi-Annual Data
Dec23
Dec24
Cash-to-Debt
0.44
0.88
MIL:OTO vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Otofarma SpA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Otofarma SpA Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Otofarma SpA's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Otofarma SpA's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Otofarma SpA (MIL:OTO) has a Cash-to-Debt of 0.88 as of Dec. 2024. This is 33% above median its historical median of 0.66. Over the past decade, Otofarma SpA's Cash-to-Debt has ranged from 0.44 to 0.88. According to the industry distribution chart, Otofarma SpA ranks #512 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 60.8%.
Is Otofarma SpA's Cash-to-Debt too high?
Otofarma SpA's current Cash-to-Debt of 0.88 is 33% above median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 0.88. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Otofarma SpA's value of 0.88 is 46.2% below this industry median. Based on the distribution chart, Otofarma SpA ranks #512 out of 842 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Otofarma SpA has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Otofarma SpA's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Otofarma SpA ranks #512 out of 842 companies for Cash-to-Debt. This places Otofarma SpA in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Otofarma SpA's value of 0.88 is 46.2% below this benchmark. Historically, Otofarma SpA's own Cash-to-Debt has ranged from 0.44 to 0.88 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 1.64, Otofarma SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Otofarma SpA's current Cash-to-Debt of 0.88 is 46.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Otofarma SpA's current Cash-to-Debt is 0.88, which is 33% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Otofarma SpA stock overvalued right now?
Otofarma SpA (MIL:OTO) has a current Cash-to-Debt of 0.88. The current Cash-to-Debt is 0.88, which is 33% above median its 10-year median of 0.66 and 46.2% below the Medical Devices & Instruments industry median of 1.64. Otofarma SpA's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Otofarma SpA (MIL:OTO), the current Cash-to-Debt is 0.88 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Otofarma SpA is engaged in the construction and production of hearing aids, is constantly growing in the audiological field to provide adequate responses to every type of hearing aid need to its customers who require the possible personalized application of custom-made hearing aids. It provides otoacoustic medical devices and TELEMEDICINE services exclusively in affiliated pharmacies, possessing a portfolio of Instrumental IT patents.
18GF Score
Get the complete analysis for MIL:OTO
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:OTO has been successfully added to your 
